221 related articles for article (PubMed ID: 32669083)
1. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.
Azevedo Martins JM; Rabelo-Santos SH; do Amaral Westin MC; Zeferino LC
BMC Cancer; 2020 Jul; 20(1):660. PubMed ID: 32669083
[TBL] [Abstract][Full Text] [Related]
2. [Key enzymes of degradation and angiogenesis as a factors of tumor progression in squamous cell carcinoma of the cervix].
Solov'eva NI; Timoshenko OS; Kugaevskaia EV; Andreeva IuIu; Zavalishina LE
Bioorg Khim; 2014; 40(6):743-51. PubMed ID: 25895371
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN.
Branca M; Ciotti M; Giorgi C; Santini D; Di Bonito L; Costa S; Benedetto A; Bonifacio D; Di Bonito P; Paba P; Accardi L; Syrjänen S; Favalli C; Syrjänen K;
Anticancer Res; 2006; 26(2B):1543-56. PubMed ID: 16619570
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization.
Davidson B; Goldberg I; Kopolovic J; Lerner-Geva L; Gotlieb WH; Weis B; Ben-Baruch G; Reich R
Gynecol Oncol; 1999 Mar; 72(3):380-6. PubMed ID: 10053110
[TBL] [Abstract][Full Text] [Related]
5. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization.
Davidson B; Goldberg I; Kopolovic J; Lerner-Geva L; Gotlieb WH; Ben-Baruch G; Reich R
Gynecol Oncol; 1999 Jun; 73(3):372-82. PubMed ID: 10366463
[TBL] [Abstract][Full Text] [Related]
6. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes.
Cid S; Eiro N; Fernández B; Sánchez R; Andicoechea A; Fernández-Muñiz PI; González LO; Vizoso FJ
Clin Breast Cancer; 2018 Feb; 18(1):e123-e133. PubMed ID: 28927692
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer.
Jobim FC; Xavier NL; Uchoa DM; Cruz DB; Saciloto M; Chemello N; Schwartsmann G
Braz J Med Biol Res; 2009 Oct; 42(10):979-87. PubMed ID: 19787153
[TBL] [Abstract][Full Text] [Related]
9. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
Zhou CY; Yao JF; Chen XD
Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
[TBL] [Abstract][Full Text] [Related]
10. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
Zhang S; Li L; Lin JY; Lin H
World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
[TBL] [Abstract][Full Text] [Related]
11. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
12. [Expression and significance of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in non-melanoma skin cancer].
Fu XR; Zhang C; Chen CY; Zhang L; Wang LX; Wang BH; Liu XY; Zhang MZ
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):369-73. PubMed ID: 22883459
[TBL] [Abstract][Full Text] [Related]
13. Stromal cells play a role in cervical cancer progression mediated by MMP-2 protein.
Fernandes T; de Angelo-Andrade LA; Morais SS; Pinto GA; Chagas CA; Maria-Engler SS; Zeferino LC
Eur J Gynaecol Oncol; 2008; 29(4):341-4. PubMed ID: 18714566
[TBL] [Abstract][Full Text] [Related]
14. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases.
Sato T; Sakai T; Noguchi Y; Takita M; Hirakawa S; Ito A
Gynecol Oncol; 2004 Jan; 92(1):47-56. PubMed ID: 14751137
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinase-1, -9, -13, and tissue inhibitor of metalloproteinases-1 in basal cell carcinomas of the eyelid.
Zlatarova ZI; Softova EB; Dokova KG; Messmer EM
Graefes Arch Clin Exp Ophthalmol; 2012 Mar; 250(3):425-31. PubMed ID: 21881840
[TBL] [Abstract][Full Text] [Related]
16. Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.
Brun JL; Cortez A; Lesieur B; Uzan S; Rouzier R; Daraï E
Oncol Rep; 2012 Apr; 27(4):1049-57. PubMed ID: 22200690
[TBL] [Abstract][Full Text] [Related]
17. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
18. [Membrane type 1 matrix metalloproteinase (MT1-MMP) and the regulators of its activity as invasive factors in squamous cell cervical carcinomas].
Timoshenko OS; Gureeva TA; Kugaevskaia EV; Solov'eva NI
Biomed Khim; 2014; 60(6):683-8. PubMed ID: 25552509
[TBL] [Abstract][Full Text] [Related]
19. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma.
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Nesland JM; Berner A; Bryne M; Reich R
Clin Exp Metastasis; 1999; 17(10):799-808. PubMed ID: 11089877
[TBL] [Abstract][Full Text] [Related]
20. Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix.
Davidson B; Goldberg I; Liokumovich P; Kopolovic J; Gotlieb WH; Lerner-Geva L; Reder I; Ben-Baruch G; Reich R
Int J Gynecol Pathol; 1998 Oct; 17(4):295-301. PubMed ID: 9785129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
